BMO Capital has raised its price target for Welltower Inc. (WELL) to $240 from $225, while reaffirming an Outperform rating on the stock. This adjustment reflects continued positive sentiment from analysts towards the healthcare real estate investment trust. Other firms like UBS and Cantor Fitzgerald have also recently increased their price targets for Welltower, maintaining Buy and Overweight ratings, respectively, suggesting broad analyst confidence in the company’s future performance.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BMO Capital Adjusts Welltower Price Target to $240 From $225, Maintains Outperform Rating
BMO Capital has raised its price target for Welltower Inc. (WELL) to $240 from $225, while reaffirming an Outperform rating on the stock. This adjustment reflects continued positive sentiment from analysts towards the healthcare real estate investment trust. Other firms like UBS and Cantor Fitzgerald have also recently increased their price targets for Welltower, maintaining Buy and Overweight ratings, respectively, suggesting broad analyst confidence in the company’s future performance.